{"schema_version":"secwatch.filing_event.v1","accession":"0001323885-22-000055","form_type":"8-K","ticker":"ATRC","cik":"0001323885","company_name":"AtriCure, Inc.","filed_at":"2022-05-03T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.211905+00:00","generated_at":"2026-06-26T01:19:18.269325+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"AtriCure Q1 revenue $74.6M (+25.8% YoY); guides FY22 rev $318-330M","bullets":["Revenue $74.6M, up 25.8% YoY; U.S. $62.3M (+23.8%), intl $12.3M (+37.2%).","Gross margin 74.5% vs 75.1% YoY; operating loss narrowed to $14.2M from $15.9M.","GAAP net loss $0.33/share; adjusted loss $0.33/share; adj EBITDA loss $4.2M.","FY 2022 rev guidance $318-330M (+16-20%); adj EPS loss $1.07-$1.12.","CEO cites broad-based growth; EPi-Sense adoption, Cryo Nerve Block expansion, EnCompass launch."],"urls":{"canonical":"https://secwatch.observer/filing/0001323885-22-000055","json":"https://secwatch.observer/filing/0001323885-22-000055.json","markdown":"https://secwatch.observer/filing/0001323885-22-000055.md","text":"https://secwatch.observer/filing/0001323885-22-000055.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1323885/000132388522000055/0001323885-22-000055-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1323885/000132388522000055/atrc-20220503.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T01:19:18.269325+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}